MYB/AKT3 axis is a key driver of ovarian cancer growth, aggressiveness, and chemoresistance
MYB/AKT3 axis drives ovarian cancer growth, aggressiveness, and chemoresistance, highlighting its potential as a therapeutic target in ovarian cancer.
Authors
- Ajay P. Singh (ORCID: https://orcid.org/0000-0003-3492-6330)
- S. K. Srivastava (ORCID: https://orcid.org/0000-0001-9611-1001)
- Rodney P. Rocconi (ORCID: https://orcid.org/0000-0001-8642-5859)
- Orlandric Miree
- Kunwar Somesh Vikramdeo (ORCID: https://orcid.org/0000-0002-6016-2672)
- Amod Sharma
- Shashi Anand (ORCID: https://orcid.org/0000-0002-7226-7113)
- Seema Singh (ORCID: https://orcid.org/0000-0002-7188-3803)
Institutions
- State Street (United States) (US)
- University of Mississippi Medical Center (US)
- USA Mitchell Cancer Institute (US)
- University of South Alabama (US)
Publication Details
- Journal
- Journal of Ovarian Research
- Published
- 2025-08-11
- DOI
- https://doi.org/10.1186/s13048-025-01761-9
- Citations
- 4
- Primary Topic
- RNA modifications and cancer
- Type
- article
- Field-Weighted Citation Impact
- 3.22
Funders
- University of South Alabama
- National Institutes of Health